Advances in Breast Cancer Research
Vol.2 No.4(2013), Paper ID 36732, 8
pages
DOI:10.4236/abcr.2013.24022
Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer
Russell Burcombe, Steve Chan, Richard Simcock, Kunal Samanta, Fran Percival, Peter Barrett-Lee
Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK
Nottingham University Hospitals NHS Trust, Nottingham, UK
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
Roche Products Ltd., Welwyn Garden City, UK
pH Associates Ltd., Marlow, UK
Velindre Cancer Centre, Cardiff, UK
Copyright © 2013 Russell Burcombe, Steve Chan, Richard Simcock, Kunal Samanta, Fran Percival, Peter Barrett-Lee et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Burcombe, R. , Chan, S. , Simcock, R. , Samanta, K. , Percival, F. and Barrett-Lee, P. (2013) Subcutaneous Trastuzumab (Herceptin
®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer.
Advances in Breast Cancer Research,
2, 133-140. doi:
10.4236/abcr.2013.24022.